biostudies-literatureUnknown9Tornyos DGliflozins altering the sodium-glucose transport protein 2 (SGLT2) in the nephron, represent alone or in combination a promising treatment option for patients with type II diabetes mellitus. In addition to glucose control, these drugs provide benefits including reduced risk of long-term cardiovascular (CV) and renal complications. Several trials evaluated gliflozins in patients with various degrees of cardiac dysfunction with heterogeneous results. We aimed to perform a comprehensive analysis of the effect of gliflozins on CV outcomes. Systematic searches of electronic databases were conducted until September 2022. Multiple treatment network meta-analysis was performed in R. Random-effects model was used to combine risk estimates across trials calculating risk ratio (RR) with 95% confidencFrontiers in cardiovascular medicine1041200https://www.ebi.ac.uk/biostudies/studies/S-EPMC9760750biostudies-literatureCardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials.PMC9760750Faludi RTornyos DEl Alaoui El Abdallaoui OKupo PKomocsi AMeuer MLukacs RfalseCardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials.Gliflozins altering the sodium-glucose transport protein 2 (SGLT2) in the nephron, represent alone or in combination a promising treatment option for patients with type II diabetes mellitus. In addition to glucose control, these drugs provide benefits including reduced risk of long-term cardiovascular (CV) and renal complications. Several trials evaluated gliflozins in patients with various degrees of cardiac dysfunction with heterogeneous results. We aimed to perform a comprehensive analysis of the effect of gliflozins on CV outcomes. Systematic searches of electronic databases were conducted until September 2022. Multiple treatment network meta-analysis was performed in R. Random-effects model was used to combine risk estimates across trials calculating risk ratio (RR) with 95% confidenc2022-01-01T00:00:00Z20222025-04-26T09:47:08.88Z2025-04-06T13:09:56.759ZS-EPMC97607503654502410.3389/fcvm.2022.1041200